

Resource Summary Report

Generated by [NIF](#) on Sep 21, 2026

EFM-192A

RRID:CVCL_1812

Type: Cell Line

Proper Citation

RRID:CVCL_1812

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1812

Proper Citation: RRID:CVCL_1812

Description: Cell line EFM-192A is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast carcinoma

Defining Citation: [PMID:10969801](#), [PMID:19582160](#), [PMID:22460905](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: EFM-192A

Synonyms: EFM192A, EFM192

Cross References: CLO:CLO_0002889, EFO:EFO_0006568, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN03471045, BioSample:SAMN10988213, cancercellines:CVCL_1812, Cell_Model_Passport:SIDM01002, Cosmic:1309000, Cosmic:1995391, Cosmic:2165004, Cosmic-CLP:1290798, DepMap:ACH-000117, DSMZ:ACC-258, DSMZCellDive:ACC-258, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1290798, GEO:GSM274641, GEO:GSM344365, GEO:GSM344415, GEO:GSM350532, GEO:GSM843498,

GEO:GSM847316, GEO:GSM847470, GEO:GSM886998, GEO:GSM888067, GEO:GSM1172858, GEO:GSM1172950, GEO:GSM1421429, GEO:GSM1669755, IARC_TP53:28290, LiGeA:CCLE_198, LINCS_HMS:51114, LINCS_LDP:LCL-1478, Pharmacodb:EFM192A_322_2019, PRIDE:PXD030304, Progenetix:CVCL_1812, Wikidata:Q54832052

ID: CVCL_1812

Record Creation Time: 20220427T215830+0000

Record Last Update: 20260920T002526+0000

Ratings and Alerts

No rating or validation information has been found for EFM-192A.

No alerts have been found for EFM-192A.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Perurena N, et al. (2026) EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators. Cancer research, 86(6), 1467.

Luque M, et al. (2026) Cancer-associated fibroblast-derived protein S100-A11 influences the response to anti-HER2 therapies in HER2-positive breast cancer. Neoplasia (New York, N.Y.), 78, 101318.

Mahdi AF, et al. (2025) Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast Cancer. International journal of molecular sciences, 26(2).

Kim H, et al. (2023) Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages. Cell reports, 42(10), 113256.

Kim J, et al. (2022) KS10076, a chelator for redox-active metal ions, induces ROS-mediated STAT3 degradation in autophagic cell death and eliminates ALDH1+ stem cells. Cell reports, 40(3), 111077.

Tognetti M, et al. (2021) Deciphering the signaling network of breast cancer improves drug sensitivity prediction. Cell systems, 12(5), 401.

Guardia C, et al. (2021) Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 27(18), 5096.

Strack E, et al. (2020) Identification of tumor-associated macrophage subsets that are associated with breast cancer prognosis. *Clinical and translational medicine*, 10(8), e239.

Watson SS, et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. *Cell systems*, 6(3), 329.